» Articles » PMID: 28647858

Counter-intuitive Plasma Vitamin D and Zinc Status in HIV-1-infected Adults with Persistent Low-level Viraemia After Treatment Initiation: a Pilot Case-control Study

Overview
Publisher Springer
Date 2017 Jun 26
PMID 28647858
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Determinants of persistent low-level viraemia [PLLV, a viral load (VL) of between 50 and 500 copies/mL] have not been elucidated. In a case-control study, we evaluated the influence of micronutrients on PLLV in a population of 454 HIV-1 adults having initiated antiretroviral therapy (ART) between January 2007 and December 2011. Plasma levels of retinol (vitamin A), 25-OH vitamin D + D, vitamin E and zinc were measured at ART initiation in cases (PLLV after 6 months of ART) and in controls (VL <50 copies/mL after 6 months). Cases and controls were matched for the CD4 cell count (±50/mm) and ethnic origin. Intergroup differences in demographic, biological and treatment parameters and sunshine intensity at ART initiation were adjusted using a propensity score. A receiver operating characteristic (ROC) curve was used to assess intergroup differences in plasma micronutrient levels. Thirty-three of the 454 patients (7.3%) displayed PLLV (median VL: 92 copies/mL). Patients were predominantly male (89%), Caucasian (64%) and CDC stage C (25%). The median age was 38 years, the median initial VL was 5.2 log copies/mL and the median CD4 count was 74/mm. The 22 cases and matched controls were balanced in these respects, and had similar vitamin A/E levels. Two cases (9%) and 9 controls (41%) had a vitamin D level <10.3 ng/mL (p = 0.0015), and 2 cases (9%) and 10 controls (48%) had a zinc level <74.6 μg/dL (p = 0.04). Our results support in vitro studies suggesting that vitamin D favours HIV-1 replication and that HIV-1 is zinc-dependent. Wide-scale, prospective studies are required.

Citing Articles

Influencing factors and adverse outcomes of virologic rebound states in anti-retroviral-treated individuals with HIV infection.

Yuan D, Li M, Zhou Y, Shi L, Lu J, Fu G J Virus Erad. 2023; 9(1):100320.

PMID: 37008574 PMC: 10063406. DOI: 10.1016/j.jve.2023.100320.

References
1.
DAgostino Jr R . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265-81. DOI: 10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b. View

2.
Borel P, Preveraud D, Desmarchelier C . Bioavailability of vitamin E in humans: an update. Nutr Rev. 2013; 71(6):319-31. DOI: 10.1111/nure.12026. View

3.
Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, Bernard J . High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother. 2012; 67(9):2222-30. DOI: 10.1093/jac/dks176. View

4.
Arnaud J, Touvier M, Galan P, Andriollo-Sanchez M, Ruffieux D, Roussel A . Determinants of serum zinc concentrations in a population of French middle-age subjects (SU.VI.MAX cohort). Eur J Clin Nutr. 2010; 64(10):1057-64. DOI: 10.1038/ejcn.2010.118. View

5.
Lee S, Xiao J, Knutson J, Lewis M, Han M . Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry. 1997; 36(1):173-80. DOI: 10.1021/bi961849o. View